Kamada (XTAE:KMDA) Accounts Payable & Accrued Expense : ₪83.3 Mil (As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Kamada Accounts Payable & Accrued Expense?

Kamada's quarterly accounts payable & accrued expense increased from Sep. 2023 (₪73.9 Mil) to Dec. 2023 (₪93.0 Mil) but then declined from Dec. 2023 (₪93.0 Mil) to Mar. 2024 (₪83.3 Mil).

Kamada's annual accounts payable & accrued expense increased from Dec. 2021 (₪94.3 Mil) to Dec. 2022 (₪123.1 Mil) but then declined from Dec. 2022 (₪123.1 Mil) to Dec. 2023 (₪93.0 Mil).

Kamada Accounts Payable & Accrued Expense Historical Data

The historical data trend for Kamada's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kamada Accounts Payable & Accrued Expense Chart

Kamada Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

91.67

60.22

94.31

123.08

93.05

Kamada Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															123.20	129.24	73.90	93.05	83.34

Kamada Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Kamada (XTAE:KMDA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kamada Ltd (XTAE:KMDA) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

KMDA:USA

Address

2 Holzman Street, P.O. Box 4081, Science Park, Rehovot, ISR, 7670402

Website

https://www.kamada.com

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.